Navigation Links
Access Pharmaceuticals Announces Poster Presentations on ProLindac,at the American Association for Cancer Research 2007 Annual Meeting

preclinical models and in human trials. The Company believes that ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed DACH platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and one in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer in 2007.

About Access

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.

CONTACT: Stephen B. Thompson, Vice President and Chief Financial Officerof Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations,Donald C. Weinberger, or media, Alisa Steinberg, both of Wolfe
'"/>




Page: 1 2 3 4

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by AstraZeneca ... is an important drug for the treatment of ... 2000, quetiapine was listed in the Catalogue of ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... At the end of 2009, the vaccine industry raised ... business media were occupied by various kinds of news ... successfully landed on the Nasdaq, then Simcere, a pharmaceutical ... announced a 50.8% stake in Ealong Biotech and took ...
... EAST HANOVER, N.J., Oct. 16 Novartis announced today ... safety profile of once-yearly Reclast® (zoledronic acid) injection in ... 1,200 women was presented this weekend at the annual ... Research (ASBMR) in Toronto, ON, Canada. The ...
Cached Medicine Technology:Vaccine Leaders All Over the World Talking About China Vaccine Opportunities at VacChina 2010 -- the No.1 China Focused Vaccine Partnering Forum 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
(Date:8/28/2015)... ... August 28, 2015 , ... ... at the Zoo to celebrate children helping children, a thank you to the ... West Ohio have contributed to the United Methodist initiative to end malaria deaths. ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering music ... second year to the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. ... to support music education in the underfunded school districts of Mendon and its neighboring ...
(Date:8/28/2015)... MD (PRWEB) , ... August 28, 2015 , ... As ... system from Merz, received FDA clearance for results that last for two years, ... is exciting news for patients who are looking for a long-lasting, effective solution for ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... or those who might personally be struggling with chemical dependency, may be able ... Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in Western ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices, recently released Visio Stencils for ... Series, HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... to moms who took it in first 3 months more ... News) -- Infants whose mothers take folic acid (folate) during ... according to a Norwegian study. , Folate is recommended to ... their flour with folic acid. , The researchers examined data ...
... - A long history of terrorism in India precedes ... Database (GTD), maintained at the University of Maryland by ... Responses to Terrorism (START) counts more than 4,100 terrorist ... thousands. This information is freely available online. , The ...
... of a new health website providing in-depth news on lung cancer. , ... and more patients are finding out that information is one of the ... Responding to the growing demand for accurate information about lung ... News is introducing Lung Cancer News Today to offer exactly the kind ...
... residents need protected sleep periods and increased supervision of work ... according to a new Institute of Medicine report funded by ... , The report is the result ... the relationship between residents, work schedules, their performance and the ...
... VSCP ), a leading provider of quantitative imaging ... $27 million,compared to $14.7 million at the same time ... calculates backlog as the amount remaining to be,recognized from ... within the backlog ranges from 2 months to 6 ...
... Medical Journal study finds natural, less expensive treatments are ... , PRINCETON, N.J., Dec. 2 ... season is, for most, anticipated with excitement. But ... Irritable Bowel Syndrome (IBS), the holidays can be fraught ...
Cached Medicine News:Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:India terrorism by the numbers 2Health News:EIN News Introduces 'Lung Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Holiday Season Brings New Hope to Millions Who Suffer from Common Chronic Health Disorder 2
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
Medicine Products: